By Thomas Anderson and Rotem Petranker — 2018
There is a growing research literature suggesting psychedelics hold incredible promise for treating mental health ailments ranging from depression and anxiety to PTSD. But how do we know for sure?
Read on theconversation.com
CLEAR ALL
This presentation summarizes past and ongoing studies from the Johns Hopkins Psilocybin Research Project, which started about 15 years ago.
1
Dr. Roland R. Griffiths is a clinical pharmacologist at Johns Hopkins. Dr. Griffiths has been researching mood-altering compounds for over 40 years, has published over 360 times, and started the psilocybin research program at Johns Hopkins nearly 2 decades ago.
Bestselling author Tim Ferriss (Tools of Titans, The 4-Hour Workweek, etc.) probes the science, mysteries, and future of psychedelics with Dr. Roland R. Griffiths, a clinical pharmacologist at Johns Hopkins. Dr.
Dr Robin Carhart-Harris talks about his scientific research into the effects and potential therapeutic uses of psychedelic drugs. Join him as he discusses brain imaging work involving psilocybin, the active ingredient of magic mushrooms, and explains how the drug works in the brain.
New research using psychedelic drugs to understand the brain could lead to new treatments for mental disorders such as depression.
The talk will review brain imaging work on the action of psychedelics on the brain and describe the results of a clinical trial assessing psilocybin as a treatment for depression. It will also review the broader societal impact of psychedelic drug-use and discuss its implications.
Abstract: Highlighting the results of two fMRI studies and one MEG study with psilocybin and an fMRI study with MDMA, Carhart-Harris will report the effects of both drugs on regional brain activity and brain network organization.
Dr. Robin Carhart-Harris, of the Neuropsychopharmacology Unit, Imperial College London, discusses research on Psilocybin and how psychedelics could be used in therapy to help with depression, addiction, and other problems of rigid thought patterns.
Robin has been conducting pioneering brain imaging studies of psychedelic drugs. Most recently, he has completed the first phase of a clinical trial looking at the potential of psilocybin to treat depression, and his talk looks at how these drugs can be used in treatment.
The Beckley Foundation Scientific Program conducts cutting edge research with LSD in human subjects, explores neurophysiological similarities between LSD and the mystical experience through observing modulations in the blood supply, brainwaves and a broad spectrum of cognitive changes.